BeOne Medicines Director Sells $0.53M in ADS Under 10b5-1 Plan
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BeOne Medicines (ONC) filed a routine Form 4 disclosing that Director and Scientific Advisory Board Chair Xiaodong Wang sold an aggregate 2,007 American Depositary Shares (each equal to 13 ordinary shares) on 06/24/2025 under a Rule 10b5-1 plan at prices ranging from $263.40 – $267.81. The total consideration is roughly $0.53 million, representing about 0.3 % of his total beneficial ownership. No new grants, derivative transactions, or governance changes were reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | American Depositary Shares | 300 | $263.50 | $79K |
| Sale | American Depositary Shares | 1,100 | $265.3525 | $292K |
| Sale | American Depositary Shares | 507 | $266.5653 | $135K |
| Sale | American Depositary Shares | 100 | $267.81 | $27K |
| Holding | Ordinary Shares | -- | -- | -- |
| Holding | Ordinary Shares | -- | -- | -- |
| Holding | Ordinary Shares | -- | -- | -- |
| Holding | Ordinary Shares | -- | -- | -- |
Footnotes (8)
- F1. These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.
- F2. These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.
- F3. These securities are held by the spouse of the Reporting Person.
- F4. Each American Depositary Share represents 13 Ordinary Shares.
- F5. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.40 to $263.55, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.02 to $265.86, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.27 to $266.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was the total value of the ONC insider sale reported on 06/24/2025?
Did the June 2025 Form 4 significantly change Xiaodong Wang's ownership in ONC?
Was the insider sale executed under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.